PRNewswire June 25, 2003 (2:55 PM EST)

Latest Headlines PRNewswire Archives

OmniComm's TrialMaster(R) Selected As EDC Solution By Barrier Therapeutics PRINCETON, N.J. and FORT LAUDERDALE, Fla., June 25 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc (OTC Bulletin Board: OMCM) a leading developer of Internet-based technology solutions that streamline the process of collecting, validating and managing clinical trial data, is pleased to announce that Barrier Therapeutics Inc. has selected OmniComm's star product TrialMaster(R) as its product of choice. Barrier will use TrialMaster in their Seboride clinical trial for the treatment of seborrheic dermatitis. This trial will take place in the USA and in Europe involving 40 clinical research sites and 840 subjects. "We have closely followed the evolution of the TrialMaster product over the last few years, and are confident that this latest EDC product of OmniComm will enhance Barrier's capabilities to complete our large scale Seboride project in a timely and cost-efficient manner," said Geert Cauwenbergh, Chairman and CEO of Barrier Therapeutics Inc. "We are very pleased that Barrier Therapeutics has chosen TrialMaster for its EDC requirements", said Cornelis Wit, President and CEO of OmniComm. "We, like Barrier Therapeutics, are both young and emerging companies that strive for maximum efficiency in our operations and we are confident that TrialMaster will meet the high standards that Barrier Therapeutics has set. TrialMaster is known for having the fastest set-up time in the industry, and OmniComm is extremely service oriented." About OmniComm OmniComm is one of the fastest-growing companies in the EDC market, targeting its product TrialMaster(R) to the Pharmaceutical and Device industry, Biotechnology companies and CROs. Apart from those industries, OmniComm counts among its clients such prestigious organizations as Columbia University and the NIH. During the recent annual Drug Industry Association's conference, EDC (Electronic Data Capture) vendors were invited to demonstrate their product's ability by participating in the EDC-Olympics. TrialMaster(R) turned out to be the only product that could complete all the given tasks within the time limits set and deliver a good, solid, ready-to-use format. The complete version can be viewed at http://www.EDColympics.com About Barrier Therapeutics Inc Barrier Therapeutics, Inc. is a specialty pharmaceutical company focused on the development of novel dermatological therapeutics. The privately held company was formed to develop and market dermatological products based on intellectual property initially in-licensed from affiliates of Johnson & Johnson. Barrier's current clinical pipeline includes three products in, or entering, Phase III Clinical Trials to treat fungal infections, Candida- associated diaper dermatitis, and seborrheic dermatitis. The earlier-stage clinical products -- for psoriasis, acne, skin inflammation, fungal infections, allergies, and wound healing -- are complemented by a broad portfolio of preclinical candidates. The Company is headquartered in Princeton, New Jersey and has a wholly owned subsidiary in Geel, Belgium. Web site: www.barriertherapeutics.com Safe Harbor Disclaimer Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements this press release other that historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1993, Section 21E of the Securities Exchange of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results. More information about OmniComm is available on its home page at http://www.omnicomm.com .